Project Grant R44AI188680
Award Date
12/17/24
Completion Date
5/31/25
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Baebies, Inc. (NZSZBQ9B84T1)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Sherlock Biosciences, Inc. a $298,948 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a power-free, molecular diagnostic device for detecting Chlamydia trachomatis and Neisseria gonorrhoeae from self-collected vaginal swabs. The goal is to create an accurate, easy-to-use, and inexpensive diagnostic solution that can be deployed in point-of-need settings, thereby...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $796,454 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University to develop a rapid antimicrobial susceptibility testing (AST) platform for Neisseria gonorrhoeae (NG). The platform will utilize single-cell mRNA profiling to assess transcriptional responses to antimicrobials within 10 minutes, providing clinicians with personalized treatment recommendations...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $297,761 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Biological Mimetics, Inc. to develop a sensitive, rapid, and affordable CRISPR-based diagnostic test for malaria parasites. The Phase I project aims to design and optimize a multi-chambered, instrument-free diagnostic assay that can detect malaria targets without advanced training or equipment, making it suitable for resource-limited...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $499,151 Project Grant (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a novel diagnostic test for early-stage syphilis. The project aims to create an innovative immuno-PCR platform that can detect unique peptidoglycan fragments shed by the syphilis-causing bacterium Treponema pallidum. This represents a significant advancement over current serological tests, which can...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $299,170 Project Grant to Latde Diagnostics Corp., a woman-owned small business, to develop a rapid, equitable, lateral flow-based antibiotic susceptibility test (AST) for urinary tract infections (UTIs). The goal of this Phase I project is to demonstrate the feasibility of the Metabolic Amino Acid Phenotyping (MAAP) test kit, which can provide...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $999,997 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Inbios International Inc., a minority-owned biotechnology company in Seattle, WA. The grant, awarded on May 8, 2024, supports the development of a next-generation "Chagas Detect Plus" rapid test for the sensitive and specific diagnosis of Chagas disease, an infectious condition caused by the parasite...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $212,357 Project Grant (CFDA 93.855) to the University of Texas at Austin to develop a new point-of-care nucleic acid test (POC NAT) for rapid and accurate detection of syphilis, including congenital syphilis in newborns. The project aims to address the growing syphilis epidemic through a "triad approach" that includes: 1) developing a POC NAT on a microfluidic device with colorimetric readout for easy...
The University of Victoria, through its Advancement Services division, was awarded a $260,760 Project Grant (R21AI186005) from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research). The funding will be used to develop a direct diagnostic test for infectious and congenital syphilis that exhibits high sensitivity and specificity, can differentiate active versus past infections and syphilis from yaws, and can be adapted to a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research program) provides $163,698 to Magic Lifescience, Inc. to develop a novel point-of-care (POC) molecular diagnostic assay for syphilis detection. The award aims to create a multiplexed genital ulcer disease (GUD) panel test utilizing giant magnetoresistive (GMR) biosensors. This innovative POC platform is designed to rapidly detect Treponema...